An endocrinologist offers perspective on his reaction to EMPEROR-REDUCED topline results and what he hopes to see from the full results at ESC 2020.
Welcome to The Endocrine Outlook, hosted by Senior Editor of Endocrinology Network, Patrick Campbell.
In this episode, we discuss reaction to topline results from the EMPEROR-REDUCED trial examining the use of empagliflozin for heart failure in patients with and without diabetes with endocrinologist Robert Busch, MD, a practicing endocrinologist with the Endocrine Group.
Announced on July 30, by Boehringer Ingelheim and Lilly, topline results indicate the use of empagliflozin was associated with a decrease in the composite endpoint of CV death and worsening heart failure. Scheduled to be presented at ESC 2020, the results will be presented 1 year after the results of DAPA-HF.
Now, results of EMPEROR-REDUCED have a chance to firmly cement the notion that the benefit on heart failure, which was proven with dapagliflozin in DAPA-HF are present with empagliflozin—reaffirming the benefit on heart failure is truly a class effect of SGLT2 inhibitors.